PT3119752T - Compostos 3,4-diamino-6-cloropirazina-2-carboxamida para o tratamento de doenças mediadas por enac - Google Patents

Compostos 3,4-diamino-6-cloropirazina-2-carboxamida para o tratamento de doenças mediadas por enac

Info

Publication number
PT3119752T
PT3119752T PT157133398T PT15713339T PT3119752T PT 3119752 T PT3119752 T PT 3119752T PT 157133398 T PT157133398 T PT 157133398T PT 15713339 T PT15713339 T PT 15713339T PT 3119752 T PT3119752 T PT 3119752T
Authority
PT
Portugal
Prior art keywords
chloropyrazine
diamino
treatment
mediated diseases
carboxamide compounds
Prior art date
Application number
PT157133398T
Other languages
English (en)
Inventor
Elisabeth Berglund Susanne
Connolly Stephen
Hemmerling Martin
Hossain Nafizal
Kristoffersson Anna
Rune Michael Lundkvist Johan
Nikitidis Grigorios
Elisabeth Ripa Lena
Shamovsky Igor
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT3119752T publication Critical patent/PT3119752T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT157133398T 2014-03-18 2015-03-17 Compostos 3,4-diamino-6-cloropirazina-2-carboxamida para o tratamento de doenças mediadas por enac PT3119752T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461954674P 2014-03-18 2014-03-18

Publications (1)

Publication Number Publication Date
PT3119752T true PT3119752T (pt) 2018-07-24

Family

ID=52780553

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157133398T PT3119752T (pt) 2014-03-18 2015-03-17 Compostos 3,4-diamino-6-cloropirazina-2-carboxamida para o tratamento de doenças mediadas por enac

Country Status (38)

Country Link
US (3) US9873678B2 (pt)
EP (1) EP3119752B1 (pt)
JP (1) JP6502469B2 (pt)
KR (1) KR102296041B1 (pt)
CN (1) CN106103423B (pt)
AP (1) AP2016009447A0 (pt)
AR (1) AR099790A1 (pt)
AU (1) AU2015233195B2 (pt)
CA (1) CA2941807C (pt)
CL (1) CL2016002303A1 (pt)
CR (1) CR20160479A (pt)
CY (1) CY1120509T1 (pt)
DK (1) DK3119752T3 (pt)
DO (1) DOP2016000232A (pt)
EA (1) EA029952B1 (pt)
ES (1) ES2679618T3 (pt)
GT (1) GT201600190A (pt)
HR (1) HRP20181123T1 (pt)
HU (1) HUE039425T2 (pt)
IL (1) IL247610B (pt)
LT (1) LT3119752T (pt)
ME (1) ME03056B (pt)
MX (1) MX368577B (pt)
NI (1) NI201600134A (pt)
NZ (1) NZ724063A (pt)
PE (1) PE20170205A1 (pt)
PH (1) PH12016501808B1 (pt)
PL (1) PL3119752T3 (pt)
PT (1) PT3119752T (pt)
RS (1) RS57487B1 (pt)
SG (1) SG11201607751SA (pt)
SI (1) SI3119752T1 (pt)
SV (1) SV2016005278A (pt)
TR (1) TR201810207T4 (pt)
TW (1) TWI687410B (pt)
UY (1) UY36034A (pt)
WO (1) WO2015140527A1 (pt)
ZA (1) ZA201607136B (pt)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577418A (en) 1969-02-12 1971-05-04 Merck & Co Inc Pyrazinamide derivatives and processes for their preparation
US3573306A (en) 1969-03-05 1971-03-30 Merck & Co Inc Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides
IE52345B1 (en) 1981-02-02 1987-09-16 Ici Plc Alkanolamine derivatives
EP0086564B1 (en) 1982-01-29 1985-11-21 Imperial Chemical Industries Plc Alkanolamine derivatives
GB8810933D0 (en) 1987-05-26 1988-06-15 Ici America Inc Heterocyclic compounds
GB8810934D0 (en) 1987-05-26 1988-06-15 Ici America Inc Amides
US4803206A (en) 1988-03-07 1989-02-07 Schering Corporation Antihypertensive acylpyrazines
GB8812343D0 (en) 1988-05-25 1988-06-29 Ici America Inc Amino compounds
GB8812342D0 (en) 1988-05-25 1988-06-29 Ici America Inc Bicyclic compounds
JP3771591B2 (ja) 1997-02-26 2006-04-26 ファイザー・インク ヘテロアリールヘキサン酸アミド誘導体、それらの製造法およびそのCCR1レセプターと結合するMIP−1αの選択的な阻害剤としてのそれらの使用
GB9930557D0 (en) 1999-12-23 2000-02-16 Rolic Ag Optically active materials
KR100840816B1 (ko) 2000-05-12 2008-06-23 젠자임 코포레이션 TNF-α시그널링의 조절물질
AP2004003049A0 (en) 2001-11-08 2004-06-30 Elan Pharm Inc N,N' -substituted-1,3-diamino -2-hydroxypropane derivatives.
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040087571A1 (en) 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
WO2004056775A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
MX2007004536A (es) 2004-10-13 2007-07-17 Univ Connecticut Ligandos de lipido canabinergico.
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JP5330274B2 (ja) 2007-03-01 2013-10-30 ノバルティス アーゲー Pimキナーゼ阻害剤およびその使用方法
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2011520831A (ja) 2008-05-13 2011-07-21 ノバルティス アーゲー 3,5−ジアミノ−6−クロロ−ピラジン−2−カルボン酸誘導体および気道疾患処置用上皮性ナトリウムチャネルブロッカーとしてのその使用
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
ES2535736T3 (es) * 2008-06-10 2015-05-14 Novartis Ag Derivados de pirazina como bloqueadores de los canales de sodio epitelial
WO2011028740A1 (en) * 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US9505735B2 (en) 2012-06-21 2016-11-29 Whitehead Institute For Biomedical Research Compounds for treating infectious diseases
EP2931713B1 (en) 2012-12-17 2016-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds

Also Published As

Publication number Publication date
JP6502469B2 (ja) 2019-04-17
SI3119752T1 (en) 2018-08-31
CN106103423B (zh) 2019-12-06
AP2016009447A0 (en) 2016-09-30
NZ724063A (en) 2018-02-23
LT3119752T (lt) 2018-08-10
US10336725B2 (en) 2019-07-02
TWI687410B (zh) 2020-03-11
EA201691641A1 (ru) 2017-02-28
ME03056B (me) 2018-10-20
RS57487B1 (sr) 2018-10-31
KR102296041B1 (ko) 2021-08-30
AU2015233195B2 (en) 2017-04-20
CR20160479A (es) 2017-02-24
TW201620880A (zh) 2016-06-16
CA2941807C (en) 2023-03-07
CN106103423A (zh) 2016-11-09
IL247610B (en) 2019-05-30
SG11201607751SA (en) 2016-10-28
TR201810207T4 (tr) 2018-08-27
US9873678B2 (en) 2018-01-23
KR20160127135A (ko) 2016-11-02
SV2016005278A (es) 2016-11-30
UY36034A (es) 2015-09-30
EP3119752A1 (en) 2017-01-25
HUE039425T2 (hu) 2018-12-28
PE20170205A1 (es) 2017-04-06
AR099790A1 (es) 2016-08-17
NI201600134A (es) 2017-03-13
WO2015140527A1 (en) 2015-09-24
PH12016501808A1 (en) 2017-01-09
AU2015233195A1 (en) 2016-09-22
MX2016011681A (es) 2016-10-28
DOP2016000232A (es) 2016-10-16
ZA201607136B (en) 2018-04-25
DK3119752T3 (en) 2018-07-30
CY1120509T1 (el) 2019-07-10
GT201600190A (es) 2019-07-29
IL247610A0 (en) 2016-11-30
HRP20181123T1 (hr) 2018-09-21
US10954211B2 (en) 2021-03-23
CL2016002303A1 (es) 2017-01-13
US20190330187A1 (en) 2019-10-31
ES2679618T3 (es) 2018-08-29
PL3119752T3 (pl) 2018-09-28
JP2017512830A (ja) 2017-05-25
EP3119752B1 (en) 2018-05-16
MX368577B (es) 2019-10-08
US20180162838A1 (en) 2018-06-14
CA2941807A1 (en) 2015-09-24
US20170107195A1 (en) 2017-04-20
PH12016501808B1 (en) 2017-01-09
EA029952B1 (ru) 2018-06-29

Similar Documents

Publication Publication Date Title
HK1244280B (zh) 用於治療感染性疾病的吡嗪化合物
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
HK1244485A1 (zh) 用於治療神經母細胞瘤的組合物
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
HK1232220A1 (zh) 用於治療心血管疾病的 -苄基異喹啉衍生物
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
IL259381B (en) Miravegron for the treatment of retinal diseases
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
HRP20181123T1 (hr) Spojevi 3,4-diamino-6-kloropirazin-2-karboksamida za liječenje bolesti posredovanih s enac
LT3903774T (lt) N,n-bis-2-merkaptoetilizoftalamidas, skirtas neurodegeneracinių ligų gydymui
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
ZA201704589B (en) Compounds for the treatment of cancer